Malignant gliomas are highly invasive and chemoresistant brain tumors with extremely poor prognosis. Targeting of the soluble factors that trigger invasion and resistance therefore could have a significant impact against the infiltrative glioma cells that are a major source of recurrence. Fibulin-3 is a matrix protein that is absent in normal brain but upregulated in gliomas and promotes tumor invasion by unknown mechanisms. Here, we show that fibulin-3 is a novel soluble activator of Notch signaling that antagonizes DLL3, an autocrine inhibitor or Notch, and promotes tumor cell survival and invasion in a Notch-dependent manner. Using a strategy for inducible knockdown, we found that controlled downregulation of fibulin-3 reduced Notch signaling and led to increased apoptosis, reduced self-renewal of glioblastoma initiating cells, and impaired growth and dispersion of intracranial tumors. In addition, fibulin-3 expression correlated with expression levels of Notch-dependent genes and was a marker of Notch activation in patient-derived glioma samples. These findings underscore a major role for the tumor extracellular matrix in regulating glioma invasion and resistance to apoptosis via activation of the key Notch pathway. More importantly, this work describes a non-canonical, soluble activator of Notch in a cancer model and demonstrates how Notch signaling can be reduced by targeting tumor-specific accessible molecules in the tumor microenvironment.
Introduction
Malignant gliomas are the most common primary brain tumors and one of the types of cancer with worst prognosis (1, 2) . Despite significant advances in neurosurgery and chemoradiotherapy, gliomas remain highly resistant to conventional treatments and improvements in patient outcome have been modest (3) . A major challenge for glioma therapy is the typical scattering of invasive tumor cells in the brain, escaping resection and leading to recurrence (4) .
Cumulative evidence suggests that these invasive cells are highly resistant to cytotoxic therapies (5, 6) and that their dispersion may be triggered, in part, by these treatments (7, 8) . Improved targeting of the mechanisms that promote glioma invasion and facilitate chemoresistance is therefore critical to increase the long-term efficacy of current therapeutic approaches.
The discovery and characterization of glioma-initiating, stem-like cells (GICs) that share properties with neural stem cells (9) has brought attention to a number of signaling pathways in glioma that are also involved in neural development, such as Hedgehog, Wnt and Notch (10, 11) . These pathways are necessary for the maintenance of GICs (12, 13) and critical for glioma initiation, self-renewal, and progression through stages of malignancy (11, 14) , all of which makes them appealing pharmacological targets. While Hedgehog and Wnt are activated by soluble factors, Notch activation is usually a juxtacrine signaling mechanism that mediates close cell-to-cell signaling (15) , which becomes less likely as tumor cells scatter. A few soluble, non-canonical activators of Notch signaling have been described in mammals (e.g.: MAGP-1/2, CCN3, and YB-1 (15)) but their relationship with Notch signaling in cancer progression has not been elucidated.
The fibulins are a family of secreted proteins that associate to the extracellular matrix (ECM) scaffold, forming anchoring structures that can regulate cell proliferation and migration (16, 17) . Several fibulins have been associated with the development of solid tumors such as ovarian, breast, and colorectal cancers (16, 17) , but their role in cancer initiation and progression has been difficult to define (16) (17) (18) . Fibulin-3, also known as EFEMP1, is a protein of restricted expression in the body, predominantly localized in the ECM of elastic tissues (19) . This protein is absent from normal brain (19, 20) and is downregulated in several types of solid tumors (21, 22) . Surprisingly, fibulin-3 is highly upregulated in gliomas, where it promotes tumor growth and invasion (22) . Recent results suggest that fibulin-3 is also upregulated in some highly metastatic tumors, where it correlates with the progression of these tumors towards the invasive phenotype (23, 24) . The molecular mechanisms of this protein in cancer are still essentially unknown.
Here, we report that fibulin-3 is a novel soluble activator of Notch signaling, acting through an unconventional mechanism that reduces cis-inhibition of Notch. Our results show that fibulin-3 regulates the Notch pathway in glioma and promotes resistance to apoptosis as well as tumor growth and invasion in a Notch-dependent manner. This is the first demonstration of a secreted matrix molecule that regulates the Notch pathway in cancer to promote tumor progression.
Materials and Methods:
Cells and tissue specimens: The human glioblastoma cell lines U87 and U251 and the rat glioblastoma cell line CNS1 were cultured as previously described (22) and authenticated using the "Cell Check" service provided by the Research Animal Diagnostic Laboratory (RADIL, Columbia MO). Primary glioblastoma-derived initiating cells (GICs G2, G8, G34 and G146) were kindly provided by Drs. E. Chiocca and I. Nakano of the Department of Neurological Surgery, OSU, and cultured as floating neurospheres in DMEM/F-12 supplemented with 2 ȝM glutamine, 20 ng/ml EGF, 20 ng/ml bFGF, 2 ȝg/ml grade-1A heparin and B27 supplement (Invitrogen). These cells were validated for self-renewal, ability to form tumors in low numbers, 
DNA constructs, siRNAs and lentivirus:
A clone containing the full-length coding sequence of fibulin-3 was previously described (22) . From this clone, the variants fib-3Δn and fib-3Δc were generated by deleting the sequences Glu 19 -Ser 106 and Cys 379 -Phe 493 , respectively. Full-length DLL3 cDNA (25) was subcloned into pCDNA4.1-V5/His for expression and epitope-tagging.
The following constructs have already been described (26, 27) and were used without modifications: full-length rat Notch-1 (pBOS-rNotch1), full-length rat Jagged-1 (pBOS-SN3T),
constitutively active mouse Notch-1 intracellular domain (pSG5-FLAG-NICD), and a Notchreporter construct carrying firefly luciferase under control of 4xCBF1 binding elements (pGL2Pro-CBF1-Luc). Comparison of N-terminal sequences of fibulin-3 and Notch ligands was performed using ClustalW software (Supplemental Figure S1 ).
SiRNA oligonucleotides against fibulin-3 and Notch-1 were purchased from Qiagen and validated at the mRNA and protein levels (Supplemental Figure S2 ).
The lentiviral vector pLVET-tTR-KRAB-eGFP used for doxycycline-dependent shRNA expression has been described (28) . shRNAs against fibulin-3 or a non-targeting control sequence (Genscript) were cloned into the shuttle vector pLVTHM and then subcloned into the lentiviral backbone. After stable transduction, tumor cells were treated with 20 μg/ml doxycycline for 48h to induce shRNA and eGFP expression. Inducible fibulin-3 knockdown was confirmed in three independent glioma cell lines (Supplemental Figure S3) .
Immunohistochemistry: Human tissue sections (5 μm) were deparaffinized and processed for
Research. immunohistochemistry with antibodies against fibulin-3 and Hes1 (listed in Supplemental Table   I ). Scoring was performed blindly by a pathologist (GN), using a scale from 0 (absent staining) to 100 (whole visual field stained) (29) . Frozen mouse brains were coronally sectioned at 20 ȝm and every fourth section stained with 0.1 % w/v cresyl violet (22) . Imaging software (ImageJ v.1.45) was used to measure maximum coronal area and distance from the geometrical center of the tumor to the most distant border. Sections selected for immunohistochemistry were probed with an antibody against the proliferation marker Ki67 (22) or processed for TUNEL staining (Apoptag Red kit, Millipore).
Biochemical assays: Cells were recovered from culture, lysed and processed for Western blotting using standard protocols (22) (antibodies are listed in Supplemental Table I ). To analyze protein phosphorylation, cells were incubated in serum-free media overnight before treatments. In vitro effects of fibulin-3 were analyzed by incubating glioma cells with purified fibulin-3 (100 ng/ml) for 2h. Short-time incubations (15 min) were also performed to compare activity of fibulin-3 against a canonical EGFR ligand (EGF, 5 ng/ml). For semi-quantitative RT-PCR, cells or tissue samples were processed using Trizol reagent (Invitrogen) and total RNA was purified by ethanol precipitation. For Notch-reporter assays, cells were transfected with the Notch-reporter construct and Renilla luciferase as loading control. Reporter cells were exposed to purified fibulin-3 for 8 hours or co-transfected with different constructs and processed after 24 h to quantify luciferase activity. fixed, stained and counted (30) . Invasion of cells out of spheroids implanted in cultured brain slices was performed as described (30) and total dispersion quantified by fluorescence microscopy. The gamma-secretase inhibitor DAPT (25 μM, Tocris) was added to the cells 2h before seeding and maintained in the medium during these experiments. Transfection with cDNAs or siRNAs was performed 48 h before preparing cell spheroids to deposit on brain slices.
Migration and invasion assays:
Cell viability and self-renewal: Cell viability was monitored using a standard redox assay (Promega CellTiter kit). Cells treated with serum depletion or temozolomide (Tocris) were labeled with propidium iodide/annexin-V following standard protocols and analyzed using a replicates (eight replicates for brain slice invasion assays). Animals studies were performed with N=5 (histology) or N=10 (survival) animals per experimental condition. Results were analyzed by one-factor or multifactorial ANOVA, followed by Bonferroni's post-hoc test.
Immunohistochemical scoring was analyzed using Spearman non-parametric rank correlation.
Survival curves were compared by log-rank test.
Results

Fibulin-3 is a paracrine activator of Notch signaling:
Fibulin-3 binds to large ECM proteins with lower affinity than other members of this family (19) , therefore being a largely soluble factor (22) . Other than its binding to ECM proteins, the molecular mechanisms triggered by fibulin-3 are almost completely unknown.
We first investigated if fibulin-3 could activate the EGFR pathway in glioma cells because this mechanism has been described in pancreatic carcinoma cells (32) , although opposite results have been shown in nasopharyngeal carcinomas (33) . We used a conventional glioma cell line promoted Notch-1 cleavage and upregulation of the active Notch-1 intracellular domain (NICD) ( Figure 1A ), an effect that has never been described for the members of the fibulin family.
To validate this finding, we generated reporter HEK293 cells, which do not express fibulin-3, expressing full-length Notch-1 and a RBPJk-dependent Notch-responsive luciferase reporter (26) . These cells were co-cultured in equal proportion with HEK293 cells expressing fibulin-3 or the canonical Notch ligand, Jagged-1. The luciferase reporter was activated in both cases, demonstrating that Notch signaling was activated by fibulin-3 from neighboring cells ( Figure   1B were essentially undistinguishable from those of full-length fibulin-3, suggesting that the DSLlike motif was critical for Notch pathway activation.
Fibulin-3 antagonizes the cis-inhibitor of Notch, DLL3:
We next investigated if the effects of fibulin-3 were a result of direct binding to Notch-1 but could not detect co-precipitation of these two proteins. Similarly, we were unable to detect any effect of fibulin-3 on the activity of the proteases ADAM10/ADAM17 involved in Notch activation (not shown).
Therefore, we focused on a possible effect of fibulin-3 on the mechanism of cis-inhibition that regulates Notch activity. Notch ligands of the Delta family are known to increase Notch activity when expressed in a neighboring cell (trans-activation) but inhibit Notch when expressed in the same cell as Notch (cis-inhibition) (15) . The Notch ligand DLL3 is unique in that it acts as a cis-inhibitor of Notch receptors expressed in the same cell but lacks trans-activating activity (25) .
Using CNS1 glioma cells, we observed that transient upregulation or knockdown of fibulin-canonical ligand Jagged-1. Together, these results suggested that the Notch-activating effect of fibulin-3 was likely mediated by downregulating DLL3 or blocking the inhibitory effect of DLL3 over Notch.
Fibulin-3 regulates Notch activity and correlates with Notch activation in glioma:
We next investigated if the expression of fibulin-3 in gliomas effectively correlated with Notch activity. Overexpression of fibulin-3 in glioma cells resulted in significant upregulation of Notch-dependent genes such as Hes1 ( Figure 3A ) and Hes5 ( Figure 3B ), while siRNA-mediated knockdown of fibulin-3 downregulated both genes. More importantly, the effects of fibulin-3 downregulation were reproduced using GICs, suggesting that fibulin-3 levels can modulate Notch activity in this key population of tumor cells.
To determine if the correlation between fibulin-3 levels and Notch activity was maintained in patient-derived specimens, we performed double immunohistochemistry for fibulin-3 and Hes1 in 13 controls and 52 glioma specimens. Results showed that fibulin-3 and Hes1 were very low or absent in normal tissue ( Figure 3C ) but were co-expressed in tumor cells (not shown) and their expression increased with tumor grade ( Figure 3C ). There was a significant positive correlation between fibulin-3 and Hes1 expression ( Figure 3D ) except in a small subset of anaplastic oligodendrogliomas that had low fibulin-3 expression but high levels of Hes1.
Interestingly, overexpression of NICD or knockdown of Notch-1 in glioma cells did not affect fibulin-3 expression (Supplemental Figure S4) , suggesting that fibulin-3 is not a Notch target.
Therefore, the observed correlation in gliomas was most likely due to regulation of Notch signaling by fibulin-3. Taken together, these results underscored fibulin-3 as a marker of Notch activity and potential regulator of this pathway in glioma.
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The pro-invasive effect of fibulin-3 in gliomas is Notch-dependent:
In a previous study we demonstrated that fibulin-3 promotes glioma invasion (22) but did not identify the underlying molecular mechanism. Therefore, we next asked if the pro-invasive role of fibulin-3 in gliomas would be mediated by Notch signaling.
To test this hypothesis we first analyzed cell migration in a Transwell TM assay using U251
and CNS1 cells. Fibulin-3 overexpression increased total cell migration, as expected, but this effect was abolished by DAPT ( Figure 4A ). Since DAPT did not affect baseline migration, we concluded that Notch signaling was not necessary for basal cell motility but was required to mediate the pro-migratory effect of fibulin-3.
To further determine if Notch was necessary for the pro-invasive role of fibulin-3 we analyzed cell invasion through neural ECM, using glioma spheroids implanted in cultured brain slices. This is an extensively validated model (22, 30, 34) to study glioma cell invasion under conditions that accurately reproduce the natural barriers to cell motility in the brain. Using highly invasive CNS1 cells we confirmed that the pro-invasive effect of fibulin-3 could be suppressed by DAPT ( Figure 4B ) or by transfection of the cells with Notch-1 siRNA ( Figure 4C ).
We finally investigated the pro-invasive effects of fibulin-3 on GICs, which are thought to be a key infiltrative population in gliomas (6) . Knockdown of Notch-1 reduced GIC invasion through neural ECM and completely abolished the pro-invasive effect of fibulin-3 ( Figure 4D ).
Together, these results support a novel role for Notch signaling as a pro-invasive pathway in gliomas and the major underlying mechanism for the invasive effects of fibulin-3.
Fibulin-3 promotes glioma cell survival in a Notch-dependent manner:
The Notch pathway is critically required for survival of glioma cells (35 
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could regulate glioma cell viability, making it a potential chemosensitizing target.
To test this hypothesis, U251 and CNS1 cells were transfected with control or fibulin-3-specific siRNAs and subjected to serum starvation as a simple pro-apoptotic condition. Transient knockdown of fibulin-3 was sufficient to increase the stress sensitivity of glioma cells, resulting in higher percentages of apoptotic (annexin V-positive) and necrotic (propidium iodide-positive) cells ( Figure 5A ) as well as overall reduced viability in the cultures (Supplemental Figure S5 ).
Biochemical analysis of starved CNS1 cells demonstrated that fibulin-3 knockdown increased the expression of cleaved caspase-3, a typical marker of apoptosis ( Figure 5B ). However, when fibulin-3 siRNA was co-transfected with increasing amounts of the NICD fragment, the upregulation of cleaved caspase-3 was significantly reduced upon starvation ( Figure 5C ). This result suggested that the anti-apoptotic effect of fibulin-3 was Notch-dependent and could be rescued by independent activation of Notch signaling.
To confirm if fibulin-3 downregulation could be used as a chemosensitizing strategy, U251 cells were subjected to fibulin-3 knockdown followed by briefly treatment with temozolomide, which is the standard of care cytotoxic agent for malignant gliomas. Downregulation of fibulin-3 significantly reduced cell viability in presence of temozolomide ( Figure 5D ) and increased the percentages of apoptotic and necrotic cells in a time-and dose-dependent manner ( Figure 5E ). This underscored the potential relevance of fibulin-3 downregulation for chemosensitizing strategies in gliomas.
Downregulation of fibulin-3 reduces glioma stem cell viability and self-renewal:
We next attempted to generate glioma cells with stable knockdown of fibulin-3 but these cells showed deficient growth and cell clumping (Supplemental Figure S5) , possibly due to sustained negative effects on Notch signaling. Therefore, we used a lentiviral system for doxycycline-inducible expression of shRNAs (described in methods and Supplemental Figure   S3 ). Lentiviruses carrying inducible shRNAs were used for stable transduction of glioma cells (U251 and CNS1) and GICs (G8 and G34).
Cultures transduced with shRNAs and maintained in absence of doxycycline showed similar growth curves ( Figure 6A ). In contrast, induction of fibulin-3 shRNA caused a significant loss of viability in conventional glioma cells and GICs ( Figure 6A) . We investigated the effect in GICs in further detail, asking whether fibulin-3 knockdown would affect the self-renewal ability of these cells. G8 and G34 GICs cultured in limiting dilutions after induction of fibulin-3 shRNA showed significantly reduced formation of tumorspheres, an effect that was more noticeable when the cells were processed for a second round of sphere formation ( Figure 6B ). Visual inspection of the tumorspheres showed in many cases the formation of partially dissociated cell aggregates ( Figure 6C ). These results strongly supported the pro-survival role of fibulin-3 in glioma cells.
Donwregulation of fibulin-3 reduces tumor growth and increases overall survival:
Finally, we determined whether controlled downregulation of fibulin-3 would affect tumor development in vivo. We implanted CNS1, G8 and G34 cells intracranially and induced shRNA expression after tumor implantation. The resulting gliomas showed efficient long-term downregulation of fibulin-3 and Notch-regulated genes in the tumor tissue (Supplemental Figure   S6 ). Histological ( Figure 7A ) and morphometric ( Figure 7B ) analysis demonstrated a significant reduction in size and dispersion of tumors with fibulin-3 knockdown compared to controls. This was not due to defects in cell proliferation because the proportion of Ki67-positive cells in fibulin-3-defficient tumors was not significantly different from controls (Supplemental Figure   S6 ). However, fibulin-3 knockdown resulted in a significant increase in the percentage of Our results from animal models agreed with data from human glioblastomas queried from the databases The Cancer Genome Atlas (TCGA) and Repository for Molecular Brain Neoplasia Data (REMBRANDT). Fibulin-3 was highly upregulated in the vast majority of samples from those databases (Supplemental Figure S7) . Nevertheless, survival analysis demonstrated that the small subpopulation of patients with downregulated fibulin-3 had significantly longer overall survival ( Figure 7D ). Furthermore, meta-analysis of high-grade gliomas grouped by transcriptional profile (Gene Expression Omnibus dataset GSE4271 (36)) showed that fibulin-3 levels were always higher in gliomas identified as "mesenchymal" (Supplemental Figure S7) , which have poor overall survival compared to other molecular subtypes. Together, these results underscored the potential relevance of fibulin-3 for high-grade glioma classification and prognosis.
Discussion
Malignant gliomas are highly resistant to conventional radio-and chemotherapy, which, coupled to their invasive ability, facilitates tumor recurrence. Novel pharmacological and molecular strategies are focused on targeting signaling pathways to increase apoptotic sensitivity (37, 38) and improve the efficacy of adjuvant therapies. Importantly, accumulated evidence suggests that an invasive cellular phenotype is associated with increased chemoresistance (4, 6) .
Therefore, targeting pro-invasive factors in glioma could contribute not only to reducing tumor dispersal but also to increasing the sensitivity of already dispersed malignant cells (37, 39) .
Anti-invasive treatments for glioma have targeted several potential candidates, including
Research. cytoskeletal proteins, cell-surface adhesion receptors, secreted proteases, and soluble paracrine/autocrine factors (40) . However, there has been little direct evidence of how targeting these pro-invasive factors could have a direct impact on tumor cell survival. Our results provide evidence of a molecule that is specifically expressed in gliomas compared to normal neural tissue (22) , increases tumor cell invasion and, in addition, promotes tumor cell survival by regulating a critical pathway for glioma growth and resistance to apoptosis (35) .
Fibulin-3 is a member of the "small fibulins" group (fibulins -3, -4 and -5), which have been shown to act either as pro-tumoral or tumor suppressor genes in different types of solid cancer and different stages of tumor progression (16, 17) . Their molecular mechanisms have been difficult to identify due to the multiple functions of the fibulins in cancer and the fact that their molecular partners are largely unknown. Fibulin-3 is downregulated in several types of solid tumors (21, 22) but, surprisingly, is the most upregulated member of the fibulin family in malignant gliomas (22) . We have shown clear tumor-promoting effects of fibulin-3 in gliomas, including enhanced cell invasion, increased tumor volume, and reduced animal survival (22) . A similar role of fibulin-3 has been proposed in other highly invasive tumors, such as high-grade pancreatic and cervical carcinomas (23, 41) . Surprisingly, a tumor-suppressor effect of fibulin-3 was recently reported in a non-invasive glioma model and indirectly attributed to an antiangiogenic effect (42) . Although this result is difficult to explain, it is worth noting that a previously described anti-angiogenic effect of fibulin-3 (21) was caused by a recombinant form that is absent in gliomas and lacks its critical N-terminal domain (22) . On the other hand, data from large populations of high-grade glioma patients, available from multiple databases, strongly supports the pro-tumoral role of fibulin-3 in glioma. Our previous meta-analysis of REMBRANDT and ONCOMINE data (22) and current analysis of REMBRANDT and TCGA data (Figures 7 and S7 ) demonstrate that fibulin-3 is highly and specifically upregulated in CAN-12-1060 glioma patients, increases with grade, and correlates with reduced patient survival. Taken together, the specific upregulation of this protein in gliomas and its enhancing effect on tumor growth and invasion emphasize the potential of fibulin-3 as a relevant target in the tumor microenvironment.
The Notch signaling pathway is one of the major pathways dysregulated in cancers (43) 
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A possible mechanism of fibulin-3 as antagonist of DLL3 is particularly interesting because the role of this Notch ligand in cancer is poorly, if at all, defined. Current evidence indicates that DLL3 does not trans-activate Notch but inhibits this pathway when expressed in the same cell as the Notch receptor (25) . It has been proposed that this could be partly due to the formation of a Notch-DLL3 complex retained in the endoplasmic reticulum (49) , although the localization of DLL3 is still subject of debate (25) and has not been analyzed in cancer cells. Fibulin-3 could bind to and inhibit DLL3 intracellularly, or trigger DLL3 downregulation by additional mechanisms in order to activate Notch signaling.
Interestingly, DLL3 is a signature gene of high-grade gliomas defined as "proneural" by their transcriptional profile (36) . These tumors are characterized by expression of typical markers of neural differentiation and have better prognosis than other molecularly-defined subtypes. In contrast, both fibulin-3 and its close homologue fibulin-4 are expressed at much higher levels in "mesenchymal" gliomas compared to proneural tumors (Supplemental Figure S7) . The mesenchymal subtype can be clearly differentiated from proneural gliomas by its molecular signature and is characterized by increased angiogenesis and poorer prognosis. It is tempting to speculate whether increased expression of fibulins may upregulate Notch signaling in the tumor or its microenvironment (e.g., blood vessels) and contribute to tumor progression towards the more aggressive mesenchymal phenotype, which is also the predominant phenotype upon recurrence (36). DLL3 did not affect the baseline reporter activity, but significantly blocked the enhancing effects of fibulin-3 and Jagged-1 (differences from control at *p<0.05, ***p<0.001, one-way ANOVA). 
